Janux Therapeutics, Inc.
Janux Therapeutics (Nasdaq: JANX) is a clinical-stage biopharmaceutical company developing immunotherapies for cancer and autoimmune diseases. Its proprietary platforms include TRACTr, which creates tumor-activated T cell engagers that direct T cells to attack tumor cells; TRACIr, which develops tumor-activated… From the company’s description.
Over the twelve months to Sep 30, 2026, Janux Therapeutics, Inc. reported revenue of $23.29M, up 132.9% from a year earlier, and a net loss of $99.85M. Its operating margin was −599.3%, and operations used $53.58M in cash. In fiscal 2025, it reported revenue of $10.00M, down 5.6% from fiscal 2024, and a net loss of $113.63M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Janux Therapeutics, Inc. does
In the company’s own words
Janux Therapeutics (Nasdaq: JANX) is a clinical-stage biopharmaceutical company developing immunotherapies for cancer and autoimmune diseases. Its proprietary platforms include TRACTr, which creates tumor-activated T cell engagers that direct T cells to attack tumor cells; TRACIr, which develops tumor-activated immunomodulators using CD28 costimulation; and ARM, which designs bispecific therapies intended to deplete target cells and reset immune responses. The lead clinical programs are JANX007, a PSMA-targeting candidate for metastatic castration-resistant prostate cancer, and JANX008, an EGFR-targeting candidate for solid tumors; JANX011, a CD19-targeting ARM candidate, is being studied in healthy volunteers and is intended for autoimmune diseases. The company also pursues additional pipeline programs and collaborates with Merck and Bristol Myers Squibb on cancer-targeted therapies. Its TRACTr and TRACIr candidates use tumor-protease-cleavable masks and albumin-binding domains, while ARM programs are designed for controlled T-cell activation and target-cell depletion. Janux’s website is https://januxrx.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1817713
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Janux Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Janux Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Janux Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Janux Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Janux Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”